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Abstract
Background: Tumor-infiltrating CD8+ T cells are correlated with prolonged progression-free and overall survival in epithelial
ovarian cancer (EOC). A significant fraction of EOC patients mount autoantibody responses to various tumor antigens,
however the relationship between autoantibodies and tumor-infiltrating T cells has not been investigated in EOC or any
other human cancer. We hypothesized that autoantibody and T cell responses may be correlated in EOC and directed
toward the same antigens.
Methodologyand PrincipalFindings:Weobtained matched serum and tumor tissuefrom 35 patientswithhigh-grade serous
ovarian cancer. Serum samples were assessed by ELISA for autoantibodies to the common tumor antigen NY-ESO-1. Tumor
tissue was examined by immunohistochemistry for expression of NY-ESO-1, various T cell markers (CD3, CD4, CD8, CD25,
FoxP3, TIA-1 and Granzyme B) and other immunological markers (CD20, MHC class I and MHC class II). Lymphocytic infiltrates
varied widely among tumors and included cells positive for CD3, CD8, TIA-1, CD25, FoxP3 and CD4. Twenty-six percent (9/35)
of patients demonstrated serum IgG autoantibodies to NY-ESO-1, which were positively correlated with expression of NY-ESO-
1 antigen by tumor cells (r=0.57, p=0.0004). Autoantibodies to NY-ESO-1 were associated with increased tumor-infiltrating
CD8+, CD4+ and FoxP3+ cells. In an individual HLA-A2+ patient with autoantibodies to NY-ESO-1, CD8+ T cells isolated from
solid tumor and ascites were reactive to NY-ESO-1 by IFN-c ELISPOT and MHC class I pentamer staining.
Conclusion and Significance: We demonstrate that tumor-specific autoantibodies and tumor-infiltrating T cells are
correlated in human cancer and can be directed against the same target antigen. This implies that autoantibodies may
collaborate with tumor-infiltrating T cells to influence clinical outcomes in EOC. Furthermore, serological screening methods
may prove useful for identifying clinically relevant T cell antigens for immunotherapy.
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Introduction
Epithelial ovarian cancer (EOC) is a challenging disease that
affects more than 190,000 women worldwide each year (Interna-
tional Agency for Research on Cancer). The high mortality rate is
attributed to the fact that most patients are diagnosed with
disseminated disease, often with extensive ascites. Standard
treatment involves cytoreductive surgery followed by taxane- and
platinum-based chemotherapy [1]. Over 80% of patients are
highly responsive to frontline treatment, but 60–70% experience
disease recurrence within 2–5 years and ultimately succumb to
their disease [2,3].
Despite these unfortunate statistics, 20–30% of EOC patients
survive five years or more after diagnosis. Favorable prognostic
factors include early stage, non-serous histology, low grade, good
performance status, and optimal surgical debulking [4,5]. In
addition, several recent studies have shown a correlation between
tumor-infiltrating CD3+CD8+ T cells and favorable outcomes
[6,7]. Zhang et. al. first reported that patients with CD3+ T cell
infiltrates in tumor epithelium had increased progression-free and
overall survival [8]. This has been confirmed by two other studies
[9,10], and two groups have extended this finding to the CD8+ T
cell subset in particular [11,12]. In addition, the presence of
CD3+CD56+ T cells in ascites has been linked to platinum
sensitivity [13]. These findings are in agreement with earlier
studies showing a positive correlation between survival and
expression of interferon-c (IFN-c) [14,15], the IFN-c receptor
[16], IL-18 [17], and MHC class I [18,19], all of which are
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of tumor-infiltrating CD25+FoxP3+ T cells in EOC is correlated
with inferior survival [11,20–22]. Thus, it appears that the balance
of CD8+ effector T cells to CD25+FoxP3+ regulatory T cells is an
important determinant of clinical outcomes in EOC.
In addition to tumor-infiltrating T cells, many EOC patients
mount serum autoantibody responses to a variety of tumor antigens,
including NY-ESO-1, HOXA7, Ep-CAM, HSP-90, MUC-1 and
p53 [23–25]. In Type I diabetes and other autoimmune conditions,
the development of autoantibody responses portends tissue infiltra-
tion and destruction by autoreactive T cells [26]. We therefore
hypothesized that EOC patients may show a similar relationship
between tumor-specific autoantibody responses and tumor-infiltrat-
ing lymphocytes. This hypothesis was tested in a cohort of 35
advanced stage, high grade serous EOC cases for which matched
serum and tumor specimens were available. Using NY-ESO-1 as a
test antigen, we demonstrate for the first time a correlation between
tumor-specific autoantibodies and tumor-infiltrating T cells. Our
findings raise the possibility that autoantibodies may play a role in the
previously recognized relationship between tumor-infiltrating T cells
and clinical outcomes in EOC.
Results
Study cohort
We investigated the relationship between tumor-specific auto-
antibodies and tumor-infiltrating lymphocytes using matched
tumor and serum specimens from a retrospective cohort of 35
patients with high-grade serous EOC (Table 1). We elected to
focus on a single histological subtype, as other subclasses of EOC
exhibit distinct biological and clinical properties that might have
confounded the analysis [27]. All blood samples were collected
prior to surgery or chemotherapy, and all tumor specimens were
obtained at the time of primary cytoreductive surgery prior to
chemotherapy. Control blood samples were obtained from 60 age-
matched women with no known personal history of cancer.
Analysis of tumor-infiltrating lymphocytes
Tumor-infiltrating lymphocytes were assessed by immunohisto-
chemistry (IHC) using antibodies to a variety of immunological
markers (Figure 1, Table 2). All raw IHC data can be found in
Supplementary Tables S1 and S2. Only 23% (8/35) of evaluable
tumors showed significant CD20+ B cell infiltrates. In contrast,
94% (33/35) of tumors had detectable CD3+ T cell infiltrates.
Staining with antibodies to CD4 and CD8 revealed that 59% (20/
34) and 69% (24/35) of evaluable tumors had significant CD4+
and CD8+ cellular infiltrates, respectively. CD4+ and CD8+ cells
were strongly correlated (r=0.69, p,0.0001). All evaluable
tumors (27/27) expressed MHC class I to some degree, indicating
they could theoretically present antigen to the infiltrating CD8+ T
cells. Seventy-two percent (18/25) of tumors expressed MHC class
II and hence could theoretically present antigen to CD4+ T cells.
Since many tumors had dense CD8+ T cell infiltrates, we
analyzed tissues for TIA-1 and Granzyme B, both of which are
expressed by CD8+ cytotoxic T cells as well as natural killer cells
[28–30]. Seventy-three percent (25/34) of tumors had significant
TIA-1+ cellular infiltrates, which showed a positive correlation
with CD8+ infiltrates (r=0.83, p,0.0001) (Figure 2). In contrast,
only 20% (7/35) of the tumors had significant Granzyme B+
cellular infiltrates (data not shown); as expected, 6 of the 7 positive
tumors were also positive for CD8+ cells.
Tumors were also analyzed for cellular infiltrates expressing
FoxP3, a marker of activated T cells and regulatory T cells [31].
Sixty-six percent (23/35) of evaluable tumors had significant
FoxP3+ infiltrates (Figure 2), which were strongly correlated to
CD4+ cells (r=0.73, p,0.0001). We also evaluated expression of
CD25, an additional marker of activated and regulatory T cells
[32]. Fifty percent (17/34) of tumors had significant CD25+ cellular
infiltrates (Figure 2),which were strongly correlated with CD4+ cells
(r=0.58, p=0.0003) and FoxP3+ cells (r=0.75, p,0.0001).
We further stratified T cell infiltrates according to their
epithelial or stromal location within the tumor, as intraepithelial
CD3+/CD8+ T cells in particular have been correlated with
increased survival in EOC [8–12]. For this analysis, we first
measured the tumor composition as defined by the epithelial:stro-
mal ratio in each tissue core and then calculated the density of T
cells per unit of epithelium or stroma. As summarized in Table 3,
the density of CD3+ T cells per unit of tumor epithelium ranged
from 0–17, with a median of 4.6. In comparison, the density of
CD3+ T cells per unit of tumor stroma ranged from 0–138, with a
median of 16.3. In general, the density of CD3+ T cells in tumor
epithelium and stroma were only weakly correlated (r=0.34,
p=0.048), and there were many examples of tumors with dense
CD3+ infiltrates in epithelium but not stroma, and conversely, in
stroma but not epithelium. Similar to CD3+ cells, CD8+, CD4+,
FoxP3+ and TIA-1+ cells were generally denser in tumor stroma
than tumor epithelium (Table 3).
Composition of tumor-infiltrating lymphocytes after
neoadjuvant chemotherapy
The TMA used in the above analyses also contained an
additional cohort of 15 tumors from women who, as part of a
clinical trial, had undergone neoadjuvant platinum/taxane-based
Table 1. Clinical characteristics of the retrospective patient
cohort.
Age at surgery (years)
Mean 61.93
Std dev 15.61
Range 22.52–90.99
Median 63.61
* Overall Survival (years)
Mean 1.63
Std dev 0.703
Range 0–3.06
Median 1.69
Silverberg Grade
10
21 0
32 3
Unknown 2
Stage
I4
II 3
III 19
IV 4
Unknown 5
Total number of evaluable patients 35
*There were no deaths due to causes other than ovarian cancer, therefore
disease-specific and overall survival were equivalent.
doi:10.1371/journal.pone.0003409.t001
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cohort, these women had high-grade serous EOC. Tumors had
been resected after three cycles of carboplatinum/taxol-based
chemotherapy. Although the sample size was small, this provided a
unique opportunity to evaluate the effects of chemotherapy on
tumor-infiltrating lymphocytes. By most parameters, lymphocytic
infiltrates were similar between treated and untreated tumors.
However,treatedtumorsshoweda uniformtrendtowardsincreased
infiltration by all subsets of T cells assessed, and this increase was
significantlyhigherforCD3+ (median 80vs35,p=0.02)andCD8+
(median 78 vs 30, p=0.013) cells (data not shown).
Serum autoantibody responses to NY-ESO-1
Although ovarian cancer patients demonstrate autoantibody
responses to a broad repertoire of antigens [23–25], we focused on
one of the most immunogenic antigens, NY-ESO-1 [24,33,34].
Sixty control sera were assayed for IgG autoantibodies to
recombinant NY-ESO-1, and the mean and standard deviation
of the OD values were calculated (Supplementary Tables S1 and
S2). Individual sera were scored as positive if their OD value was
equal to or greater than two standard deviations from the mean of
control subjects. Consistent with published results, 26% (9/35) of
ovarian cancer cases demonstrated IgG autoantibodies to NY-
ESO-1, compared to only 5% (3/60) of controls (Figure 3A).
To determine whether autoantibody responses to NY-ESO-1
correlated with expression of the corresponding antigen, matched
tumor specimens were analyzed by IHC for expression of NY-
ESO-1. Of 34 evaluable tumors, 5 (14.7%) scored positive for NY-
ESO-1 antigen (Figure 3B). All five of these cases were also positive
for autoantibodies to NY-ESO-1. In contrast, 4 cases were positive
for NY-ESO-1-specific autoantibodies but negative for NY-ESO-1
antigen expression.
Correlations between autoantibody responses and
lymphocytic infiltrates
We next investigated whether serum autoantibodies to NY-
ESO-1 were correlated with tumor-infiltrating lymphocytes. For
this analysis, we considered epithelial and stromal T cell infiltrates
separately, as described above. We classified cases as being positive
or negative for autoantibodies to NY-ESO-1 using a cut-point of
two standard deviations from the mean of the control group
(Supplementary Tables S1 and S2). By Mann Whitney t test,
patients with autoantibodies to NY-ESO-1 had a significantly
greater stromal density of CD8+ cells (p=0.011), FoxP3+ cells
(p=0.013), and CD4+ cells (p=0.026). Thus, autoantibodies to
NY-ESO-1 showed a significant correlation to T cell infiltrates,
especially in tumor stroma.
Recognition of NY-ESO-1 by autoantibodies and tumor-
infiltrating CD8+ T cells from the same patient
The correlation between autoantibodies to NY-ESO-1 and
tumor-infiltrating T cells suggested the possibility that tumor-
infiltrating T cells may recognize NY-ESO-1 in seropositive
patients. To address this issue, we collected blood, tumor and
ascites specimens from a prospective cohort of 15 newly diagnosed
serous EOC patients. Two patients were positive for serum
autoantibodies to NY-ESO-1. Of these, one case (IROC013) was
HLA-A2+, allowing T cells to be enumerated by flow cytometry
with HLA-A2 pentamers loaded with a known CD8+ epitope from
NY-ESO-1 (Figure 4A). NY-ESO-1-specific CD8+ T cells were
rare in peripheral blood from this patient (0.22% of CD8+ cells),
but were enriched in ascites and solid tumor (1.53% and 6.64% of
CD8+ cells, respectively). Furthermore, T cells from ascites and
solid tumor produced IFN-c in response to NY-ESO-1 peptide
(Figure 4B) but not control peptides derived from p53, HER-2/neu
or WT-1 (data not shown). Indeed, in ascites the response to NY-
ESO-1 was almost as strong as that seen to the CEF viral control
peptides. Intriguingly, tumor tissue from this patient showed dense
CD3+ and CD8+ T cell infiltration of tumor stroma but not
epithelium (Figure 4C), similar to the pattern commonly seen with
autoantibody-positive patients in the retrospective cohort. Despite
mounting a strong humoral and T-cell response to NY-ESO-1,
solid tumor from this patient stained negative for expression of
NY-ESO-1 antigen; however, ascites from this patient contained
NY-ESO-1-positive cells (Figure 4C).
Figure 1. Immunohistochemical analysis of serous ovarian
tumors showing cases with high (left) and low (right) scores for
the following markers: (A,B) CD20; (C,D) CD3; (E,F) CD4; (G,H)
CD8; (I,J) MHC Class I; and (K,L) MHC Class II.
doi:10.1371/journal.pone.0003409.g001
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Using matched serum and tumor specimens from 35 patients
with high-grade serous EOC, we have demonstrated a correlation
between tumor-infiltrating T cells and tumor-specific autoanti-
bodies. To our knowledge, this is the first study to identify such a
correlation in any human cancer. Specifically, the presence of NY-
ESO-1-specific IgG autoantibodies in serum correlated with
infiltration of tumor stroma by cells expressing CD8, CD4 and
FoxP3. Moreover, in an individual patient with autoantibodies to
NY-ESO-1, corresponding ascites and solid tumor specimens were
shown to be enriched for NY-ESO-1-reactive CD8+ T cells, as
assessed by MHC class I pentamer staining and IFN-c ELISPOT.
These findings raise the possibility that autoantibody responses
may collaborate with tumor-infiltrating T cells to influence clinical
outcomes in EOC.
In addition to NY-ESO-1-specific autoantibodies, several
factors expressed by ovarian tumors have shown a positive
correlation with tumor-infiltrating T cells, including the chemo-
kines CXCL9, CCL21, CCL22 [8], CCL2 and CCL5 [35]; p53
mutations [36]; and MHC class I [37]. Conversely, tumor-
infiltrating T cells show a negative correlation with VEGF [8], B7-
H1/PD-L1 [12], CD68+ macrophages [38] and the endothelin B
receptor [39]. Thus, multiple factors influence the composition of
tumor-infiltrating T cells in EOC.
While this study focused on a single, commonly recognized
tumor antigen, NY-ESO-1, a large number of other autoantibody
target antigens have been identified in EOC, including HOXA7,
Ep-CAM, HSP-90, MUC-1 and p53 [23–25]. Indeed, tumor-
specific autoantibody responses are common among EOC
patients. For example, Stone et al. found that 44% of newly
diagnosed EOC patients had an autoantibody response to at least
1 of a panel of 12 tumor antigens [24]. Future work will determine
whether autoantibody responses to other tumor antigens also
correlate with the presence of tumor-infiltrating T cells.
Table 2. Primary antibodies used for immunohistochemistry.
Antigen Clone Supplier Catalogue Source Concentration
NY-ESO-1 E978 Zymed 35-6200 Mouse 1/200
CD20 Polyclonal Lab Vision RB-9013 Rabbit 1/400
CD3 SP7 Lab Vision RM-9107 Rabbit 1/150
CD4 4B12 Lab Vision MS-1528 Mouse 1/10
CD8 SP16 Lab Vision RM-9116 Rabbit 1/100
FoxP3 eBio7979 eBioscience 14-7979 Mouse 1/50
CD25 4C9 Lab Vision MS-1088 Mouse 1/40
Granzyme B Polyclonal Abcam ab4059 Rabbit 1/50
TIA-1 TIA-1 Abcam ab2712 Mouse 1/50
MHC class I (A, B, C) EMR8-5 MBL D226-3 Mouse 1/500
MHC class II (DR, DP & DQ) CR3/43 Affinty BioReagents MA1-25914 Mouse 1/50
Pan-cytokeratin PCK-26 Sigma C1801 Mouse 1/300
doi:10.1371/journal.pone.0003409.t002
Figure 2. Immunohistochemical analysis of serous ovarian
tumors showing cases with high (left) and low (right) scores for
the following markers: (A,B) TIA-1; (C,D) FoxP3; and (E,F) CD25.
doi:10.1371/journal.pone.0003409.g002
Table 3. Density of lymphocyte subsets in tumor stroma
versus epithelium.
Marker * Epithelial Density * Stromal Density
Median Range Median Range
CD3 4.6 0–17 16.3 0–138
CD8 1.8 0–17 6.6 0–49
CD4 1 0–13 4 0–123
FoxP3 1 0–9 7 0–74
CD25 1.1 0–25 1.1 0–29
TIA-1 1.4 0–13 4.5 0–33
Granzyme B 0 0–6 0 0–47
CD20 0 0–3 0 0–106
*All values are reported as cells per unit area defined by the Chalkley grid.
doi:10.1371/journal.pone.0003409.t003
Immunity to Ovarian Cancer
PLoS ONE | www.plosone.org 4 October 2008 | Volume 3 | Issue 10 | e3409In contrast to serological responses, less is known about the
target antigens of tumor-infiltrating T cells in EOC. T cell
receptor (TCR) spectratyping studies have shown that tumor-
infiltrating T cells in EOC represent oligoclonal populations,
which is consistent with antigen-induced clonal expansion [40–
44]. Many studies have shown recognition of autologous tumor
cells by tumor-infiltrating T cells [45–50]. Moreover, previous
work has identified T cells specific for HER2/neu [44,51–53], p53
[54] and folate-binding protein [55,56] among tumor-infiltrating
or tumor-associated T cells. To our knowledge, the current study is
the first to demonstrate recognition of NY-ESO-1 by tumor-
infiltrating and tumor-associated (i.e., ascites derived) T cells, as
evidenced by the results for patient IROC013. Intriguingly, T cell
responses to NY-ESO-1 were undetectable in peripheral blood
from this patient, indicating a strong enrichment of this T cell
subpopulation in tumor and ascites. Indeed, the IFN-c ELISPOT
response to NY-ESO-1 was similar in magnitude to that seen with
CEF control peptides. Nonetheless, the NY-ESO-1-specific
subpopulation represented only 6.6% of all tumor-infiltrating
CD8+ T cells in this subject, indicating there are likely many other
antigens recognized by infiltrating T cells. Notably, over 80% of
ovarian cancers exhibit loss of BRCA1 and/or BRCA2 function,
leading to compromised DNA repair[57,58]. One can speculate
that the resulting genetic instability leads to the expression of
abnormal proteins that may serve as neoantigens to the host
immune system.
Although tumor infiltrating T cells are associated with
prolonged progression-free and overall survival in EOC, it remains
unclear whether this reflects an active or passive role of T cells. In
other words, do T cells actively oppose tumor growth or are they
simply markers of some other feature of the tumor that drives
outcomes? There are several lines of evidence in support of the
former possibility. First, not all T-cell subsets are associated with
prognosis; rather, favorable outcomes are linked to the CD8+
subset and poor outcomes to the CD25+FoxP3+ subset
[11,12,20,21]. Second, several factors that are associated with
active CD8+ cytolytic responses are also linked to favorable
outcomes, including expression of IFN-c [14,15], the IFN-c
Figure 3. NY-ESO-1 serum autoantibodies and antigen expression in high-grade serous ovarian cancer. (A) Serum autoantibody
responses to NY-ESO-1 in the 35-patient cohort. Autoantibody responses are reported as the number of standard deviations from the mean of 60
age- and gender-matched controls with no known personal history of cancer. (B,C) Immunohistochemical analysis of NY-ESO-1 expression in two
representative serous ovarian tumors with high (B) and negative (C) expression of the antigen.
doi:10.1371/journal.pone.0003409.g003
Immunity to Ovarian Cancer
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increased survival in ovarian cancer [18,19]. In the present study,
which focused exclusively on the serous subtype, all evaluable
tumors expressed MHC class I. Similar results have been reported
by others for serous EOC [59], suggesting the vast majority of
serous tumors are MHC class I positive and have the capacity to
present antigen to tumor-infiltrating CD8+ T cells. Third, tumor-
infiltrating T cells show significant cytotoxicity against ovarian
tumors in vitro [43,45,47,60,61]. However, it is noteworthy that
only a minority of tumors in this and another study [59] had
significant Granzyme B-positive immune infiltrates, suggesting
that cytotoxic function may be suppressed in vivo. And finally, as
discussed above, tumor-infiltrating T cells show evidence of clonal
expansion [40–44] and recognition of specific antigens [44,51–56],
as shown here for NY-ESO-1 (Figure 4). Thus, evidence is
accumulating in favor of the concept that tumor-infiltrating T cells
play an active role in promoting favorable clinical outcomes in
EOC. Similarly, in colorectal cancer, functional markers associ-
Figure 4. Analysis of the T cell response in a patient with autoantibodies to NY-ESO-1 showing the presence of NY-ESO-1 reactive
CD8+ T cells in ascites and tumor despite the lack of NY-ESO-1 expression in solid tumor. (A) MHC class I pentamer analysis
demonstrating enrichment of NY-ESO-1-specific CD8+ T cells in ascites and solid tumor compared to peripheral blood. The boxed areas and
associated numbers represent the percentage of pentamer-positive cells relative to total CD8+ cells. (B) ELISPOT analysis of IFN-c production by T
cells after stimulation with an HLA-A2-binding peptide from NY-ESO-1. Data is presented as the number of IFN-c-producing cells per 1610
6 bulk cells
from the indicated tissue compartments. (C) Immunohistochemical analysis of tumor-infiltrating CD3+ and CD8+ T cells in tumor stroma, and
expression of NY-ESO-1 antigen. While the solid tumor was negative for expression of NY-ESO-1, a fraction of cells from ascites were positive. The
cellular fraction of ascites also contained cytokeratin-positive epithelial cells, presumably of tumor origin (data not shown).
doi:10.1371/journal.pone.0003409.g004
Immunity to Ovarian Cancer
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favorable clinical outcomes [62]. This suggests that immune
modulatory strategies that enhance these naturally occurring T cell
responses may improve clinical outcomes further.
In contrast to T cell infiltrates, the relationship between tumor-
specific autoantibodies and clinical outcomes is less clear. This
issue has been studied most extensively for the tumor antigen p53,
which elicits autoantibody responses in 20–25% of EOC patients.
Goodell et. al. reported a positive correlation between autoanti-
bodies to p53 and increased overall survival in EOC [63].
However, other studies have found a negative correlation [64,65]
or no correlation [66,67]. As for NY-ESO-1, we found a trend
toward poor outcomes among patients with autoantibodies to NY-
ESO-1 in the 35-case cohort studied here (data not shown), but
this trend was not seen in an independent cohort of 35 patients
from a prior study [24] (data not shown). As discussed above, the
immune response to EOC involves multiple antigens, therefore we
believe that the prognostic significance of autoantibodies is best
addressed using an extended panel of tumor antigens and larger
patient cohorts.
The autoantibody response to NY-ESO-1 correlated to T cell
infiltration of tumor stroma as opposed to tumor epithelium. This
may reflect a statistical issue, as the absolute number of T cells was
higher in tumor stroma compared to epithelium, allowing the
stromal values to achieve statistical significance. Indeed, Spearman
rank correlation analysis showed a positive relationship between
autoantibodies to NY-ESO-1 and infiltration of tumor epithelium
by CD3+ and CD8+ cells, but this did not reach statistical
significance (data not shown). Alternatively, there may be a
biological explanation. In the Th1/Th2 paradigm, immune
responses are thought to polarize toward humoral or cytolytic
effector mechanisms [68]. Applied to our results, this would
suggest that patients with strong autoantibody responses would
have weak cytolytic responses, which may result in incomplete (i.e.,
stromal) infiltration of tumor tissue by T cells. A second possibility
is suggested by murine models where autoantibody responses have
been linked to weak CD8+ cytolytic T cell responses [69]. In this
case, it was proposed that autoantibodies facilitate uptake and
presentation of tumor antigens by B cells at the expense of
dendritic cells. Since B cells are less potent antigen presenting cells
than dendritic cells, the net result is an inferior T cell response
against the tumor [69]. A final consideration is that, in the present
study, autoantibody responses to NY-ESO-1 were correlated with
infiltration of tumor by not only CD8+ T cells, but also by CD4+
and FoxP3+ T cells. The latter cells may represent regulatory T
cells, which could inhibit cytolytic T cells responses and limit the
extent of tumor infiltration [32]. We are currently collecting
matched blood and tumor specimens from a larger, prospective
cohort of EOC patients to better understand the relationship
between tumor-specific autoantibodies, tumor-infiltrating T cells
and clinical outcomes.
Although not the primary focus of this paper, we had the
opportunity to assess the effect of neoadjuvant chemotherapy on
tumor-infiltrating T cells in 15 patients. In general, treated tumors
showed increased infiltration by all subsets of T cells, and this
reached statistical significance for CD3+ and CD8+ cells. This is
reminiscent of studies in breast cancer which showed increased T
cell infiltration after chemotherapy with taxanes [70] and other
agents [71] and an association with favorable clinical responses.
Taxanes may also promote tumor immunity by enhancing T and
NK cell activity [72–75] and antigen presentation [76]. Likewise,
platinum agents can enhance cytokine synthesis by human T cells
[77], abrogate suppressor T cell activity [78] and sensitize EOC
cells to Fas-mediated apoptosis [79]. Thus, platinum/taxane-based
chemotherapy may have favorable effects on host immunity to
EOC, a hypothesis we are currently investigating in a prospective
patient cohort.
Several groups have attempted adoptive immunotherapy of
ovarian cancer using T cells expanded from tumor-infiltrating T
cells [50,80–89]. Although promising anecdotal responses have
been reported, these efforts have generally met with limited
success. It is noteworthy that solid tumor tissue from patient
IROC013 was largely negative for expression of NY-ESO-1,
despite having NY-ESO-1-specific T cells in tumor and ascites. If
this scenario is representative of other EOC patients, it would
suggest that many tumor-infiltrating T cells may recognize
antigens that are poorly expressed by tumor tissue, possibly due
to immune selection during tumor development. If we are to
realize the promise of immunotherapy for EOC, there is a pressing
need to identify target antigens that are essential to the growth and
survival of recurrent, chemotherapy-resistant tumors. Our results
suggest that autoantibody responses hold practical value for
antigen identification and warrant further study with respect to
their role in host tumor immunity and clinical outcomes.
Materials and Methods
Study subjects
All specimens and clinical data were obtained with informed
consent under protocols approved by the Research Ethics Board of
the BC Cancer Agency and the University of British Columbia.
The retrospective case cohort consisted of 35 women with high-
grade serous ovarian cancer from whom matched serum and
tumor tissue was available (OvCaRe Ovarian Tumour Bank,
Vancouver, BC, Canada). Tumor tissue was obtained at the time
of primary surgery prior to any other treatment. Table 1 shows the
general clinical characteristics of the 35-case cohort. The
retrospective cohort also included tissue from an additional 15
women who received neoadjuvant chemotherapy prior to primary
surgery; these cases are discussed separately in Results. Blood,
ascites and tumor samples were also collected from a prospective
cohort of 15 patients through the BC Cancer Agency’s Tumour
Tissue Repository. Control serum samples were obtained from 60
women with no known personal history of ovarian cancer or other
cancers. All control subjects self reported receiving a negative
mammographic result within the past year. The age distribution of
the control cohort (mean 62.0 years, standard deviation 12.3 years,
range 45.9 to 88.9 years) was similar to that of the case cohort.
Tumor and serum specimens
Retrospective cohort. Tumor tissue was obtained during
primary cytoreductive surgery. Tissue had an ischemia time of less
than 30 minutes and spent less than 48 hours in formalin prior to
being processed in paraffin. A tissue microarray (TMA) was
constructed by taking duplicate 0.6 mm cores from tumor blocks
after review of hematoxylin- and eosin-stained sections by a
pathologist. Cores were selected from regions of tumor containing
representative proportions of epithelium and stroma, while
avoiding highly necrotic regions. TMAs were assembled using a
Pathology Devices tissue arrayer (Westminster, MD). Serum
samples from cases were collected prior to surgery or
chemotherapy. Blood samples were processed by standard
laboratory procedures.
Prospective cohort. Blood was collected prior to surgery in
heparanized Vacutainer tubes, and peripheral blood mononuclear
cells (PBMC) were isolated by Ficoll density centrifugation. HLA-
A2 status was determined by flow cytometry on a FACSCalibur
(BD Biosciences, San Jose, CA) after surface staining PBMC with
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CA). Ascites collected during surgery was centrifuged (1200 rpm
for 10 min), and red blood cells (RBCs) were removed by
treatment with ACK lysis buffer (Sigma, St. Louis, MO). Solid
tumor removed during surgery was minced with scalpels to
approximately 2 mm
2 and was then digested overnight at 4uCi n
RPMI 1640 (Invitrogen, Carlsbad, CA) containing collagenase
Type I and IV (each at 0.05 mg/ml), 0.025 mg/ml hyaluronidase
and 0.01 mg/ml DNAse I (all from Sigma, St. Louis, MO). After
digestion, material was passed through a 100 mm sterile cell
strainer to remove clumps, and the resulting single-cell suspension
was pelleted as described above.
Immunohistochemistry and immunocytochemistry
TMAs were sectioned at 5 mm onto Superfrost plus slides
(Fisher Scientific, Ottawa, ON) and incubated overnight at 37uC.
Following deparaffinization, the slides were placed in a Ventana
Discovery XT autostainer (Ventana, Tucson, AZ) for immuno-
histochemical staining. Ventana’s standard CC1 protocol was used
for antigen retrieval. Primary antibodies are listed in Table 2.
TMAs were incubated with primary antibodies for 60 minutes,
and the appropriate cross-adsorbed, biotinylated secondary
antibody (Jackson Immunoresearch, West Grove, PA) was applied
for 32 minutes. Bound antibodies were detected using the
DABMap kit (Ventana), counterstained with hematoxylin (Ven-
tana), and coverslipped manually with Cytoseal-60 (Richard Allan,
Kalamazoo, MI).
Ascites from serous ovarian cancer patients was collected and
centrifuged using a Cytospin III cytocentrifuge (Thermo Shandon,
Waltham, MA). The slides were then fixed in acetone and stored
at 280uC until subjected to immunohistochemistry using standard
protocols. The ascites sample from patient IROC013 was stained
with antibodies to NY-ESO-1, CD3, CD8 and pan-cytokeratin
(Table 2).
Histopathological analysis
Immunostained TMAs were examined independently by two
pathologists and a high degree of inter-observer concordance was
achieved (r.0.7, p,0.0001) as well as intra-observer concordance
on different sessions (r=0.79, p,0.0001). Although the TMAs
showed reasonable core retention, some cores were lost during the
sectioning process and were not evaluable for one or more
markers. Immunostaining was scored using three semi-quantitative
IHC scoring systems. For NY-ESO-1 antigen, a modified H score
approach was used [IHC score=(% positive neoplastic epithelial
cells)6(staining intensity ranked from 0 to 3)] that ranged from 0–
300. Positive was defined as an H score greater than 10; in
practice, negative cases had H scores of 0–5, whereas positive cases
had H scores ranging from 105–250. For MHC class I and II, a
simplified four category scale was used (0 to 3+); a score of $2 was
defined as positive. For immune cells, scoring was undertaken
using a Chalkley 25 point array and methods similar to those used
to assess vascular density. Briefly, each immunostained tumor was
reviewed at low magnification and the core with the highest
density of positive cells was selected. This core was then assessed at
higher magnification (620 objective) with a 25 cross hair grid
overlaid on the image. Under a 620 objective magnification, this
grid defines an area of 0.56 mm
2. The proportion of the core
occupied by tumor epithelium was estimated, as was the total
number of positive immune cells within the area of the grid. The
number of grid points that coincided with positively staining
immune cells within both epithelial and stromal areas was then
determined. Positive immune cells that touched or overlapped
with tumor epithelial compartments were counted as intraepithe-
lial. All other positive cells were counted as intrastromal. For
subsequent statistical analyses, an epithelial or stromal region was
considered positive for a given immune cell population if there
were more than five cells per unit area.
ELISA to detect serum autoantibodies to NY-ESO-1
A cDNA encoding NY-ESO-1 was amplified by reverse-
transcriptase PCR from the ovarian cancer cell line OVCAR-3.
The C-terminal 25 amino acids were truncated to improve
solubility of the protein. After sequencing, the cDNA was
subcloned into the prokaryotic expression vector pDEST17, which
adds a six-residue histidine tag at the N-terminus, and expressed in
the E. coli strain BL21AI (Invitrogen, Carlsbad, CA). Urea-soluble
recombinant NY-ESO-1 was purified on a HisTrap
TM column
(GE Healthcare, Fairfield Conn), eluted in urea buffer containing
500 mM imidazole, dialyzed in phosphate-buffered saline (PBS)
and quantified by bicinchoninic acid (BCA) protein assay (Sigma,
St. Louis, MO).
Maxisorp 96-well plates (Nunc, Roskilde, Denmark) were
coated with 0.5 mg/well of purified NY-ESO-1 in 0.1 M
carbonate buffer (33.5 mM Na2CO3, 0.1 M NaHCO3, pH 9.6)
and incubated overnight at 4uC with gentle rocking. Plates were
blocked with 3% bovine serum albumin (US Biological, Swamps-
cott MA) in Tris buffered saline (TBS) containing 0.05% Tween-
20 (3% BSA/TBST) for 2 hours at room temperature on a rapid
shaker. All washes were performed with TBS/0.1% Tween-20
using a Skanwasher plate washer (Molecular Devices, Union City,
CA). Plates were washed and incubated with patient and control
serum diluted 1:100 in 3% BSA/TBST for 1 hour at room
temperature on a rapid shaker. All sera were assayed in triplicate.
Plates were washed and incubated with goat anti-human IgG
conjugated to horseradish peroxidase (Jackson, West Grove, PA) at
1:10,000 in 3% BSA/TBST for 1 hour on a shaker at room
temperature. Plates were developed with tetramethylbenzidine
(TMB) (Neogen, Lansing, MI) for 3 minutes at room temperature
and the reaction was stopped by addition of 1N HCl. The optical
density of each well was analyzed at 450 nm on a Versamax plate
reader (Molecular Devices, Union City, CA) and analyzed using
Softmax Pro 4.8.
IFN-c ELISPOT analysis
ELISPOT plates (MSIP, Millipore, Billerica, MA) were pre-
coated overnight with 10 mg/ml anti-IFN-c capture antibody (1-
D1K-Mabtech, Cincinnati, OH) and then blocked for 2 hours at
37uC with cRPMI (RPMI 1640, 10% FBS, 2 mM L-glutamine,
50 uM 2-mercaptoethanol, 10 mM HEPES, 10 mM MEM non-
essential amino acids, 10 mM sodium pyruvate and 50 ug/ml
gentamicin). Single cell suspensions of PBMC, ascites cells or solid
tumor-derived cells were prepared in 10 ml cRPMI and plated in
triplicate at 3610
5 cells per well. Cells were either left unstimu-
lated (i.e., media only) or stimulated with HLA-A2-restricted
tumor antigen peptides (NY-ESO-1157–165,p 5 3 264–272,W T - 1 126–134,
HER-2/neu654–662;e a c ha t1 0 mg/ml); a CEF (Cytomegalovirus,
Epstein Barr, Flu) virus positive control peptide pool (10 mg/ml,
Anaspec, San Jose, CA); or the T-cell mitogen phytohemagglutinin
(PHA) (5 mg/ml). After overnight incubation at 37uC, ELISPOT
plates were washed and incubated for 2 hours at 37uCw i t h1mg/ml
biotinylated anti-human IFN-c (mAb 7-B6-1, Mabtech) followed by
development with Vectastain ABC Elite kit and Vectastain AEC
substrate reagent according to the manufacturer’s instructions
(Vector Labs, Burlingame, CA). Spots were quantified using a Zeiss
automated ELISPOT reader and reported as the number of spot-
forming cells (SFC) per 10
6 PBMC.
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Single-cell suspensions of ascites cells were depleted of red blood
cells and stained with APC-conjugated HLA-A2-NY-ESO-1157–
165 pentamer (Proimmune) according to the manufacturer’s
instructions. Pentamer staining was followed by surface staining
with PerCP-conjugated anti-CD8 (53-6.7) (BD Pharmingen). Cells
were analyzed on a BD FACSCalibur, and a minimum of 50,000
events were collected.
Statistical analysis
Spearman correlation, Mann Whitney t-tests, and log rank tests
were performed as appropriate to test statistical significance using
Graphpad Prism v4.2 (Graphpad Software, San Diego, CA).
Additional un-paired t-test analysis was performed using JMP
statistical software (v7.0) (SAS Institute, Cary, NC).
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